ILLUMINA INC.

ISIN: US4523271090 WKN: 452327109 Asset Class: Stock



Company Profile

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Financial figures, Fiscal year: from 01.01. to 31.12. 2023 2022 2021 **Financial figures** Assets Liabilities and equity Assets Liabilities and equity Assets Liabilities and equity **Current assets** 2,609,000,000 3,561,000,000 2,713,000,000 Common stock capital 2,000,000 2,000,000 2,000,000 **Fixed assets** 7,502,000,000 8,691,000,000 12,504,000,000 Equity capital of a company 5.745.000.000 6.599.000.000 10,740,000,000 1.048.000.000 2.011.000.000 1.232.000.000 Cash and cash equivalents Accrued liabilities 0 0 0 Other assets

Current liabilities		1,570,000,000		2,773,000,000		1,093,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		2,796,000,000		2,880,000,000		3,384,000,000
Different income		-		-		-
Other liabilities		620,000,000		649,000,000		915,000,000
Total assets	10,111,000,000	10,111,000,000	12,252,000,000	12,252,000,000	15,217,000,000	15,217,000,000
Ralance notes						

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	12,010	11,500	9,800
Equity ratio	56.82%	53.86%	70.58%
Debt-equity ratio	76.00%	85.66%	41.69%

Others			
	2023	2022	2021
Tax Expense Rate	-3.94%	-1.57%	13.80%

ILLUMINA INC.

ISIN: US4523271090 WKN: 452327109 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	4,504,000,000	4,584,000,000	4,526,000,000
Net income	-1,161,000,000	-4,404,000,000	762,000,000
EBIT	-1,017,406,800	-4,003,838,600	875,637,000
Operating income before taxes	-1,117,000,000	-4,336,000,000	884,000,000
Cash Flow	477,000,000	392,000,000	545,000,000
Net interest income	-19,000,000	-15,000,000	-61,000,000
Research and development expenses	1,330,000,000	1,321,000,000	1,185,000,000
Income taxes	44,000,000	68,000,000	122,000,000
Result from investments in subsidaries, associates and other	-	-	-
Revenues per employee	347,494	369,351	427,938

Board of Directors

Members of Management Board		
Stephen MacMillan	Chairman of Board of Directors	
Frances Arnold	Member of Board of Directors	
Gary Guthart	Member of Board of Directors	
Robert Epstein	Member of Board of Directors	
Scott Gottlieb	Member of Board of Directors	
Andrew Teno	Member of Board of Directors	
Caroline Dorsa	Member of Board of Directors	
Philip Schiller	Member of Board of Directors	
Scott Ullem	Member of Board of Directors	
Susan Siegel	Member of Board of Directors	
Jacob Thaysen	Chairman of Managing Board	
Carissa Rollins	Member of Executive Committee	
Joydeep Goswami	Member of Executive Committee	
Kathryne Reeves	Member of Executive Committee	
Steve Barnard	Member of Executive Committee	